AtriCure, Inc. (NASDAQ:ATRC) Stock Has Consensus Price Target of $53.30 According to Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have earned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $53.30.

ATRC has been the subject of several recent analyst reports. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Piper Sandler increased their target price on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Needham & Company LLC raised their price target on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. BTIG Research lifted their price target on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Finally, Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Regina E. Groves sold 5,313 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director directly owned 34,546 shares in the company, valued at approximately $1,873,084.12. The trade was a 13.33% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 74,868 shares of company stock worth $3,317,897. 4.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

Several large investors have recently bought and sold shares of the stock. Tidal Investments LLC grew its holdings in shares of AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock worth $534,000 after purchasing an additional 6,034 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of AtriCure in the 2nd quarter valued at about $1,002,000. Engineers Gate Manager LP grew its stake in AtriCure by 12.3% during the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock worth $1,348,000 after buying an additional 5,283 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in AtriCure during the 2nd quarter worth approximately $46,000. Finally, Allworth Financial LP lifted its stake in AtriCure by 372.8% in the second quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after buying an additional 1,204 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of AtriCure stock opened at $56.20 on Friday. AtriCure has a one year low of $25.36 and a one year high of $61.70. The company has a market cap of $2.86 billion, a PE ratio of 267.63 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The business has a 50-day simple moving average of $48.63 and a 200-day simple moving average of $36.08.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts forecast that AtriCure will post 0.29 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.